Celltrion Inc (KO:068270) — Market Cap & Net Worth
Market Cap & Net Worth: Celltrion Inc (068270)
Celltrion Inc (KO:068270) has a market capitalization of $29.89 Billion (₩44.10 Trillion) as of August 24, 2026. Listed on the KO stock exchange, this Korea-based company holds position #914 globally and #18 in its home market, demonstrating a -4.80% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Celltrion Inc's stock price ₩192300.00 by its total outstanding shares 229327192 (229.33 Million). See 068270 equity to assets ratio to understand what proportion of total assets are financed by equity.
Celltrion Inc Market Cap History: 2015 to 2026
Celltrion Inc's market capitalization history from 2015 to 2026. Data shows growth from $10.49 Billion to $29.89 Billion (11.30% CAGR). Also see 068270 current and non-current assets for a full breakdown of the balance sheet.
Celltrion Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Celltrion Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check latest Celltrion Inc stock price today for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.01x
Celltrion Inc's market cap is 0.01 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.03x
Celltrion Inc's market cap is 0.03 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $14.00 Billion | $670.58 Billion | $177.99 Billion | 0.02x | 0.08x |
| 2017 | $29.40 Billion | $949.08 Billion | $368.22 Billion | 0.03x | 0.08x |
| 2018 | $30.18 Billion | $982.07 Billion | $245.76 Billion | 0.03x | 0.12x |
| 2019 | $25.78 Billion | $1.13 Trillion | $301.03 Billion | 0.02x | 0.09x |
| 2020 | $52.15 Billion | $1.85 Trillion | $517.76 Billion | 0.03x | 0.10x |
| 2021 | $29.44 Billion | $1.91 Trillion | $579.46 Billion | 0.02x | 0.05x |
| 2022 | $24.88 Billion | $2.28 Trillion | $537.84 Billion | 0.01x | 0.05x |
| 2023 | $31.32 Billion | $2.18 Trillion | $535.65 Billion | 0.01x | 0.06x |
| 2024 | $29.14 Billion | $3.56 Trillion | $422.69 Billion | 0.01x | 0.07x |
| 2025 | $28.13 Billion | $4.16 Trillion | $1.03 Trillion | 0.01x | 0.03x |
Competitor Companies of 068270 by Market Capitalization
Companies near Celltrion Inc in the global market cap rankings as of August 24, 2026. Also see Celltrion Inc (068270) cash flow conversion for how efficiently the company converts equity into cash flow.
Key companies related to Celltrion Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #188 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #323 globally with a market cap of $83.19 Billion USD.
- CSL Ltd (AU:CSL): Ranked #475 globally with a market cap of $57.77 Billion USD ( AU$81.65 Billion AUD).
- Samsung Biologics Co Ltd (KO:207940): Ranked #564 globally with a market cap of $48.66 Billion USD ( ₩71.80 Trillion KRW).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #188 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $548.05 |
| #323 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $83.19 Billion | $834.04 |
| #475 | CSL Ltd | AU:CSL | $57.77 Billion | AU$168.30 |
| #564 | Samsung Biologics Co Ltd | KO:207940 | $48.66 Billion | ₩1551000.00 |
Celltrion Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, Celltrion Inc's market cap moved from $10.49 Billion to $ 29.89 Billion, with a yearly change of 11.30%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩29.89 Billion | +6.24% |
| 2025 | ₩28.13 Billion | -3.47% |
| 2024 | ₩29.14 Billion | -6.95% |
| 2023 | ₩31.32 Billion | +25.88% |
| 2022 | ₩24.88 Billion | -15.51% |
| 2021 | ₩29.44 Billion | -43.54% |
| 2020 | ₩52.15 Billion | +102.31% |
| 2019 | ₩25.78 Billion | -14.58% |
| 2018 | ₩30.18 Billion | +2.65% |
| 2017 | ₩29.40 Billion | +109.98% |
| 2016 | ₩14.00 Billion | +33.46% |
| 2015 | ₩10.49 Billion | -- |
End of Day Market Cap According to Different Sources
On Aug 23rd, 2026 the market cap of Celltrion Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $29.89 Billion USD |
| MoneyControl | $29.89 Billion USD |
| MarketWatch | $29.89 Billion USD |
| marketcap.company | $29.89 Billion USD |
| Reuters | $29.89 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Celltrion Inc
Celltrion, Inc., a biopharmaceutical company, engages in the development, production, and sale of development, production, and sale of medicinal products. It offers biosimilars, including Remsima for rheumatoid arthritis and inflammatory bowel disease; Truxima for non-hodgkin's lymphoma and chronic lymphocytic leukemia; Herzuma for metastatic breast and gastric cancer; Remsima SC and Yuflyma for … Read more